Ligand id: 9087

Name: defibrotide

1. Hopps SA, Borders EB, Hagemann TM. (2016)
Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: a review of the literature.
J Oncol Pharm Pract, 22 (3): 496-510. [PMID:26126501]
2. Keating GM. (2014)
Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.
Clin Drug Investig, 34 (12): 895-904. [PMID:25351934]
3. Niada R, Mantovani M, Prino G, Pescador R, Porta R, Berti F, Folco GC, Omini C, ViganĂ² T. (1982)
PGI2-generation and antithrombotic activity of orally administered defibrotide.
Pharmacol Res Commun, 14 (10): 949-57. [PMID:6818564]
4. Pescador R, Mantovani M, Prino G, Madonna M. (1983)
Pharmacokinetics of Defibrotide and of its profibrinolytic activity in the rabbit.
Thromb. Res., 30 (1): 1-11. [PMID:6687960]
5. Pescador R, Porta R, Ferro L. (1996)
An integrated view of the activities of defibrotide.
Semin. Thromb. Hemost., 22 Suppl 1: 71-5. [PMID:8807733]
6. Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL et al.. (2016)
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
Blood, 127 (13): 1656-65. [PMID:26825712]